Attgeno AB announces fully subscribed share issue to complete clinical phase II study in acute pulmonary hypertension
Attgeno AB announces that a successful share issue was completed at midsummer 2022 and resulted in SEK 20 million to a valuation of SEK 378 million after the issue. The issue consists of SEK 15 million in a rights issue to existing owners and a directed new issue of SEK 5 million to the Swedish life science focused venture fund Eir Ventures. Read More
2022, July